Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan for vasospastic angina
NL-OMON28727Recruiting
- Sponsor
- AMC Health
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of macitentan in Coronary vasospasm (CAS) (2 arms), sponsored by AMC Health. Primary endpoints: Anginal burden by duration multiplied by severity and Anginal burden by frequency multiplied by severity. Started Oct 2019; status: recruiting.
02
Drugs
macitentan
03
Conditions
Coronary vasospasm (CAS)
Beyond the preview
Go deeper on NL-OMON28727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28727.